Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

Foam technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL clinical development and all pipeline materials.

Additional information about Pacira is available at http://www.pacira.com.

This news release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward- looking statements contained in the release and anticipated presentation.

Pacira Contact: Taunia Markvicka

Vice President, Commercial Development

973-254-3565


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... DUBLIN , Nov. 21, 2014 Research ... "China Recombinant Protein Drug Industry Report, 2014-2017" report ... The Chinese recombinant protein drug market ... demand rigidity, consumption ability and the like. During 2005-2013, ... hospitals grew at a CAGR of 19.1%, and it ...
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
(Date:11/21/2014)... and VIENNA, Va. , Nov. ... care provider that operates in Southern California ... provider of remote caregiving technology. Alta will be providing ... client receiving homecare services. Logo - ... is the key to providing the kind of affordable ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... Silence Therapeutics plc (AIM: SLN) ("Silence"), a ... announces that it has entered into an agreement with ... investigate the application of Silence,s proprietary DACC delivery technology ... siRNAs ") to the pulmonary vascular endothelium. ...
... September 27, 2011 NVA237 has ... European Medicines Agency (EMA) under the brand-name Seebri® Breezhaler®, ... Studies show investigational once-daily NVA237 provides superior ... Additional data show NVA237 significantly prolonged time ...
Cached Medicine Technology:Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company 2Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company 3Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company 4NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress 2NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress 3NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress 4
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... (HealthDay News) -- As parents prepare to send their children ... an important factor in academic performance, an expert advises. ... and lunches are more alert throughout the school day and ... diet, says Mary Pat Alfaro, clinical manager of the division ...
... pharmacies and health food shops are still lacking important ... Leeds researchers. In April this year, a new ... traditional herbal medicines, such as St John,s wort and ... possible side effects, how they could interact with other ...
... multiple myeloma trial has unexpectedly revealed that the drug ... its dose level in the body, say researchers at ... G. James Cancer Hospital and Richard J. Solove Research ... is an anti-inflammatory drug, and more than 390 clinical ...
... , MONDAY, Aug. 8 (HealthDay News) -- One ... playing video games may be because the games allow them ... new study suggests. The research included hundreds of casual ... asked about their motivation for playing, as well as their ...
... 8 (HealthDay News) -- Frequent visual field testing may help ... earlier stage, a new study says. It,s important to ... can receive more aggressive treatment or more frequent follow-up, the ... the journal Archives of Ophthalmology , included 381 glaucoma ...
... Reinberg HealthDay Reporter , MONDAY, Aug. 8 ... in controlling tremors and improving motor function for those ... years, according to a small new study by Canadian ... called motor system disorders, which are caused by the ...
Cached Medicine News:Health News:Healthy Lunch and Breakfast Keep Students Alert 2Health News:Herbal remedies escape EU law 2Health News:Study urges caution with lenalidomide dosage 2Health News:Frequent Tests Help Track Progression of Glaucoma, Study Finds 2Health News:Deep Brain Stimulation Improves Parkinson's Symptoms Long-Term 2Health News:Deep Brain Stimulation Improves Parkinson's Symptoms Long-Term 3
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... The definition of dexterity in ... to grip firmly and release easily, ... comfort and security. A three- or ... control during stone retrieval. These graspers ...
... grasping technology allows the ... in a shorter length ... to the stone. The ... ergonomic one-handed operation. Supplied ...
Medicine Products: